M2 PRESSWIRE-16 April 2008-BUYINS.NET: LCUT, NSTK, PCYC, SGMO, SPIR, TRLG Have Also Been Removed From Naked Short List Today(C)1994-2008 M2 COMMUNICATIONS LTD
RDATE:16042008
BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold list: Lifetime Brands Inc. (NASDAQ: LCUT), Nastech Pharmaceutical Company Inc. (NASDAQ: NSTK), Pharmacyclics Inc. (NASDAQ: PCYC), Sangamo BioSciences Inc. (NASDAQ: SGMO), Spire Corp. (NASDAQ: SPIR), True Religion Apparel Inc. (NASDAQ: TRLG). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.
Lifetime Brands Inc. (NASDAQ: LCUT) engages in the design, development, and marketing of branded household consumer products in North America. The company primarily offers various food preparation, tabletop, and home decor products. Its food preparation products include kitchenware, cutlery and cutting boards, bakeware and cookware, pantryware and spices, fondues and tabletop entertaining, and functional glassware. The company's tabletop products comprise flatware, dinnerware, tabletop accessories, giftware, glassware, crystal, serveware, and barware. Lifetime Brands' home decor products consist of non electric lighting, wall decor, picture frames, seasonal decorations, decorative accessories, and lawn and garden decor. The company sells its products to mass merchants, specialty stores, national chains, department stores, warehouse clubs, home centers, supermarkets, and off-price retailers, as well as directly to the consumer through company-operated factory and outlet stores, mail order catalogs, and the Internet. As of December 31, 2007, the company operated 34 outlet stores in 17 states under the Farberware name and 44 factory stores in 25 states under the Pfaltzgraff name. The company was founded in 1945 and is headquartered in Garden City, New York. With 11.96 million shares outstanding and 2.42 million shares declared short as of March 2008, there is no longer a failure to deliver in shares of LCUT. According to quarterly data provided by the SEC, there were still 11,906 shares of LCUT that were failing-to-deliver as of September 27, 2007.
Nastech Pharmaceutical Company Inc. (NASDAQ: NSTK) a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on its proprietary molecular biology-based drug delivery technology. Its proprietary technologies primarily focus on the intranasal delivery of compounds ranging from small molecules to peptides and proteins. The company and its partners are developing a product portfolio across multiple therapeutic areas, including products targeted for the treatment of osteoporosis, diabetes, obesity, autism, respiratory diseases, and inflammatory conditions. In addition, the company is developing a class of therapeutics utilizing RNA interference technology to down-regulate the expression of diseases causing proteins that are over-expressed in inflammation, viral respiratory infections, and other diseases. Nastech has collaborations with Procter & Gamble Pharmaceuticals, Inc. for the development and commercialization of Parathyroid Hormone (PTH1-34) nasal spray; Amylin Pharmaceuticals, Inc. for development and commercialization of exenatide nasal spray; Novo Nordisk A/S for multiple undisclosed indications; and Par Pharmaceutical Companies, Inc. for distribution of Nastech's generic calcitonin-salmon nasal spray. It also has collaborations with Merck & Co., Inc. and QOL Medical LLC. The company was founded in 1983 and is headquartered in Bothell, Washington. With 26.79 million shares outstanding and 2.82 million shares declared short as of March 2008, there is no longer a failure to deliver in shares of NSTK. According to quarterly data provided by the SEC, there were still 147,810 shares of NSTK that were failing-to-deliver as of September 28, 2007.
Pharmacyclics Inc. (NASDAQ: PCYC) a pharmaceutical company, is developing drugs to treat cancer and other diseases. Its pharmaceutical agents are synthetic small molecules designed to target key biochemical pathways in diseased cells. The company's product candidate, Xcytrin (motexafin gadolinium) Injection, an anti-cancer agent with a novel mechanism of action, has completed Phase III trials in oncology and is in Phase II trials for patients with non-small cell lung cancer. Its products also include PCI-24781, a histone deacetylase inhibitor in Phase I trial in patients with advanced relapsed solid tumors; PCI-24783, a preclinical stage small molecule inhibitor of Factor VIIa for cancer therapy; and PCI-32765, a preclinical stage small molecule tyrosine kinase inhibitor to treat B cell malignancies and autoimmune disease. Pharmacyclics has a license agreement with the University of Texas to develop and commercialize porphyrins, expanded porphyrins, and other porphyrin-like substances covered by its patents. The company was founded in 1991 and is headquartered in Sunnyvale, California. With 25.99 million shares outstanding and 2.15 million shares declared short as of March 2008, there is no longer a failure to deliver in shares of PCYC. According to quarterly data provided by the SEC, there were still 18,776 shares of PCYC that were failing-to-deliver as of September 28, 2007.
Sangamo BioSciences Inc. (NASDAQ: SGMO) focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off; and ZFP nucleases, proteins that enable to modify DNA sequences in various ways. The company's ZFP Therapeutic, SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene, is in Phase 2 clinical trials for the treatment of diabetic neuropathy (DN). It also involves in preclinical development programs of ZFP therapeutics that focus on spinal cord injury, stroke, traumatic brain injury, neuropathic pain, and Parkinson's disease. In addition, the company has research-stage programs in X-linked severe combined immunodeficiency (X-linked SCID), hemophilia, and hemoglobinopathies. It has strategic partnerships with companies, including Dow AgroSciences, LLC and Sigma-Aldrich Corporation, as well as research and license agreements with various life sciences companies, such as Pfizer, Inc.; Novo Nordisk, Inc.; Novartis A/G; Amgen, Inc.; Kirin Brewery Company; Medarex, Inc.; and Genentech, Inc. The company was founded in 1995 and is based in Richmond, California. With 40.37 million shares outstanding and 6.32 million shares declared short as of March 2008, there is no longer a failure to deliver in shares of SGMO. According to quarterly data provided by the SEC, there were still 159,036 shares of SGMO that were failing-to-deliver as of September 28, 2007.
Spire Corp. (NASDAQ: SPIR) engages in the development, manufacture, and marketing of engineered products and services in the areas of PV solar, biomedical, and optoelectronics in the United States and internationally. The company offers specialized equipment for the production of terrestrial photovoltaic modules from solar cells. It also provides value-added surface treatments to manufacturers of orthopedic and other medical devices; develops and markets coated and uncoated hemodialysis catheters and related devices for the treatment of chronic kidney disease; and performs sponsored research programs into practical applications of advanced biomedical and biophotonic technologies. In addition, the company offers custom compound semiconductor foundry and fabrication services to customers involved in biomedical/biophotonic instruments, telecommunications, and defense applications. It also involves in compound semiconductor wafer growth, thin film and related device processing, and fabrication services. Further, Spire Corporation provides materials testing services, as well as offers services in support of sponsored research into practical applications of optoelectronic technologies. The company sells its products and services primarily through its independent sales representatives and distributors, as well as grants licenses to third parties to sell its products. Spire Corporation was founded in 1969 and is headquartered in Bedford, Massachusetts. With 8.32 million shares outstanding and 474,000 shares declared short as of March 2008, there is no longer a failure to deliver in shares of SPIR. According to quarterly data provided by the SEC, there were still 22,278 shares of SPIR that were failing-to-deliver as of September 28, 2007.
True Religion Apparel Inc. (NASDAQ: TRLG) through its wholly owned subsidiary, Guru Denim, Inc., engages in the design, development, manufacture, marketing, distribution, and sale of denim jeans and other apparel for men, women, and children. Its products include denim jeans, corduroy jeans and jackets, velvet jeans, fleece jeans and hooded sweatshirts, skirts, shorts, shirts, sweaters, and sportswear. The company markets and distributes its products under the True Religion Brand Jeans brand name primarily through sales agents and distributors to department stores, specialty retailers, and boutiques in North and South America, Asia, Europe, and Australia. The company was founded in 2002 and is headquartered in Vernon, California. With 23.57 million shares outstanding and 10.94 million shares declared short as of March 2008, there is no longer a failure to deliver in shares of TRLG. According to quarterly
data provided by the SEC, there were still 105,896 shares of TRLG that were failing-to-deliver as of September 28, 2007.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 1,900,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NETTel: +1 800 715 9999e-mail: Tom@buyins.netWWW: http://www.buyins.net
((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data prepared by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).
